12.4 FACTOR VIII, BIOSTATE, ADVATE AND DDAVP

FACTOR VIII – BIOSTATE AND ADVATE

DDAVP DESMOPRESSIN

FACTOR VIII

INDICATIONS

Factor VIII is used for the management of bleeding episodes and surgical and dental procedures in patients with Haemophilia A and von Willebrand’s disease.

DOSE AND ADMINISTRATION

All requests for Factor VIII must be discussed with the Consultant Haematologist.

Storage
Store at 2-8°C Protect from light.

Ordering
Consultant Haematologist.
One month’s notice required for planned elective surgery

BIOSTATE 250 IU & 500IU

Each pack contains one 250 IU or 500IU vial of Biostate lyophilised high-purity factor VIII concentrate, one ampoule of Water for Injection BP and a Preparation Device.

Product information is available at the CSL website

HTTP://WWW.CSL.COM.AU/S1/CS/AUHQ/1199978897194/WEB_PRODUCT_C/1196562715720/PRODUCTDETAIL.HTM

ADVATE (RECOMBINANT FACTOR VIII)

This is a synthetic form of factor VIII indicated in the treatment of patients with Haemophilia A, but not von Willebrand’s disease, as there is no von Willebrand’s factor present.

It is available from Pharmacy.

Dosage is equivalent to plasma derived factor VIII.

Product information is available at the Advate website

http://www.advate.com/
**DDAVP DESMOPRESSIN**

All requests for DDAVP must be discussed with the Consultant Haematologist to ensure that it is appropriate therapy.

**DESCRIPTION**

This is a synthetic product available from Pharmacy.


**INDICATIONS**

It is indicated in the treatment of mild Haemophilia A and von Willebrands Disease (type IIb is contraindicated). DDAVP should not be used in children under the age of 2 years.

**DOSE AND ADMINISTRATION**

A Clinical Haematologist should *always* be contacted regarding use and dosage.

Typical Paediatric dosage is 0.3 micrograms/kg diluted in 20-50 mLs Normal Saline and given IV over 10-20 minutes.

Typical Adult dosage is 0.3 micrograms/kg diluted in 100mLs Normal Saline and infused over a minimum of 30 minutes. This longer infusion time reduces the incidence of flushing, headache and gastrointestinal symptoms in some patients.

Administer 30 minutes before surgery (levels rise rapidly and remain elevated for up to 24-hours).

The decision to give follow up doses should only be made after consultation with the Haematologist.

**REFERENCES**

Advate Product Information Website http://www.advate.com/


CSL Website Product Information www.csl.com